534 related articles for article (PubMed ID: 27428432)
1. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
[TBL] [Abstract][Full Text] [Related]
2. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
[TBL] [Abstract][Full Text] [Related]
3. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
4. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
[TBL] [Abstract][Full Text] [Related]
5. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
6. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
7. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
[TBL] [Abstract][Full Text] [Related]
8. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
Front Immunol; 2018; 9():3162. PubMed ID: 30723480
[TBL] [Abstract][Full Text] [Related]
9. The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.
Kwaa AK; Goldsborough K; Walker-Sperling VE; Pianowski LF; Gama L; Blankson JN
PLoS One; 2017; 12(5):e0174516. PubMed ID: 28467486
[TBL] [Abstract][Full Text] [Related]
10. Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8
Kwaa AKR; Talana CAG; Blankson JN
J Virol; 2019 Feb; 93(3):. PubMed ID: 30404799
[TBL] [Abstract][Full Text] [Related]
11. The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
Washizaki A; Murata M; Seki Y; Kikumori M; Tang Y; Tan W; Wardani NP; Irie K; Akari H
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696466
[TBL] [Abstract][Full Text] [Related]
12. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
Rochat MA; Schlaepfer E; Speck RF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
[TBL] [Abstract][Full Text] [Related]
13. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
14. Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.
Yang H; Buisson S; Bossi G; Wallace Z; Hancock G; So C; Ashfield R; Vuidepot A; Mahon T; Molloy P; Oates J; Paston SJ; Aleksic M; Hassan NJ; Jakobsen BK; Dorrell L
Mol Ther; 2016 Nov; 24(11):1913-1925. PubMed ID: 27401039
[TBL] [Abstract][Full Text] [Related]
15.
Rosás-Umbert M; Ruiz-Riol M; Fernández MA; Marszalek M; Coll P; Manzardo C; Cedeño S; Miró JM; Clotet B; Hanke T; Moltó J; Mothe B; Brander C;
Front Immunol; 2020; 11():418. PubMed ID: 32265913
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
17. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
19. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection.
Mann JFS; Pankrac J; Klein K; McKay PF; King DFL; Gibson R; Wijewardhana CN; Pawa R; Meyerowitz J; Gao Y; Canaday DH; Avino M; Poon AFY; Foster C; Fidler S; Shattock RJ; Arts EJ
EBioMedicine; 2020 Sep; 59():102853. PubMed ID: 32654992
[TBL] [Abstract][Full Text] [Related]
20. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]